RECEPTOR

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 359180
                    [Title] => Antibody vs antibody
                    [Summary] => Antibodies protect us from parasites, germs, toxins, and other foreign substances (antigens) that may enter our body. Binding of antibodies to an antigen causes the neutralization of the substance, its immobilization and increased susceptibility to elimination by natural processes, or death in the case of an invading cell. Antibodies can be produced against virtually any foreign substance – actually, against any accessible part of the antigen – and biotechnology allows us to produce virtually unlimited amounts of any antibody whose properties we desire.
                    [DatePublished] => 2006-09-21 00:00:00
                    [ColumnID] => 135735
                    [Focus] => 0
                    [AuthorID] => 1754920
                    [AuthorName] => STAR SCIENCE By Eduardo A. Padlan, Ph.D.
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 186110
                    [Title] => Key estrogen receptor gene mutation discovered
                    [Summary] => A mutant gene that makes estrogen receptors hypersensitive has been identified and it may play an important role in the evolution of invasive breast cancer, investigators reported at the annual breast cancer symposium sponsored by the San Antonio Cancer Institute. 


                    [DatePublished] => 2002-12-01 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 140669
                    [Title] => Cardiovascular study underway
                    [Summary] => The pharmaceutical company Boehringer Ingelheim has presented before the American Heart Association’s annual meeting its extensive cardiovascular trial program ONTARGET. 


The program will investigate the additional potential of newer blood pressure-reducing medications called angiotensin II receptor blocker such as telmisartan. 


Boehringer Ingelheim will also be conducting 10 additional cardiovascular studies. 


                    [DatePublished] => 2001-11-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Antibody vs antibody

By STAR SCIENCE By Eduardo A. Padlan, Ph.D. | September 21, 2006 - 12:00am

Antibodies protect us from parasites, germs, toxins, and other foreign substances (antigens) that may enter our body. Binding of antibodies to an antigen causes the neutralization of the substance, its immobilization...

Science and Environment

Key estrogen receptor gene mutation discovered

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | December 1, 2002 - 12:00am

A mutant gene that makes estrogen receptors hypersensitive has been identified and it may play an important role in the evolution of invasive breast cancer, investigators reported at the annual breast cancer symposium...

Opinion

Cardiovascular study underway

November 19, 2001 - 12:00am

The pharmaceutical company Boehringer Ingelheim has presented before the American Heart Association’s annual meeting its extensive cardiovascular trial program ONTARGET. The program will investigate the additional...

Science and Environment